-
Forbion Portfolio Company, AM-Pharma raises €116m
July 16, 2019Forbion Portfolio Company, AM-Pharma raises €116m to conduct Pivotal Phase III Trial of recAP in acute kidney injury. Please...
0 -
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk
December 17, 2018Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia. Naarden,...
-
Forbion Appoints Dr. Carlo Incerti as Operating Partner
November 29, 2018Naarden, The Netherlands, and Munich, Germany, 29 November 2018 – Forbion, a leading European life science venture capital firm,...
-
Forbion Co-leads $54m Series A Financing in newly formed Gotham Therapeutics
October 11, 2018Naarden, The Netherlands, and Munich, German, 10 October 2018 – Forbion, a leading European life sciences venture capital firm,...
-
Forbion closes oversubscribed Fourth Life Sciences VC Fund at EUR 360million
October 1, 2018Naarden, The Netherlands, and Munich, Germany, 1 October 2018 – Forbion, a leading European life science venture capital firm,...
-
Forbion exceeds target with €270 million first close of its fourth life sciences VC fund
July 12, 2018Naarden, The Netherlands, and Munich, Germany, 11 July 2018 – Forbion, a leading European life science venture capital firm,...
-
Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for the treatment of Cystic-fibrosis, COPD and severe asthma
April 12, 2018Press Release Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for...
-
Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)
March 16, 2018Press Release Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)...
-
Forbion leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases
March 13, 2018Press Release Forbion leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORγt...
-
Forbion’s portfolio company ARGENX has successfully been listed on the NASDAQ stock exchange
May 23, 2017Naarden, May 22, 2017 We are pleased to announce that our portfolio company argenx (Euronext Brussels: ARGX) has successfully...
